◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Anthem Biosciences Limited (ANTHEM) Revenue 2022–TTM

Name: Anthem Biosciences Limited (ANTHEM) revenue history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-01

Anthem Biosciences Limited annual revenue for fiscal TTM was ₹20.0 billion, a decrease of 5.7% from ₹21.2 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

ANTHEM Annual Revenue

Revenue (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹20.0B	₹21.2B	₹18.4B	₹14.2B	₹10.6B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANTHEM Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹4.2B	₹6.1B	₹4.2B	₹5.5B	₹5.4B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

BIOCON Revenue — Biocon Limited
ABBV Revenue — AbbVie
6160 Revenue — BeOne Medicines AG
AMGN Revenue — Amgen
GILD Revenue — Gilead Sciences
VRTX Revenue — Vertex Pharmaceuticals

More ANTHEM metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All ANTHEM financial statements → Interactive ANTHEM charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.